Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromesLudwig Kappos, Rupert Sandbrink, D. H. Miller et al.|Neurology|2006Cited by 677
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromesLudwig Kappos, Rupert Sandbrink, Chris H. Polman et al.|American Journal of Ophthalmology|2006Cited by 551
Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT studyLudwig Kappos, Rupert Sandbrink, Mark S. Freedman et al.|The Lancet|2007Cited by 502
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trialLudwig Kappos, Christoph Pohl, Mark S. Freedman et al.|The Lancet Neurology|2009Cited by 370
Lack of Association between Antimyelin Antibodies and Progression to Multiple SclerosisJens Kühle, Rupert Sandbrink, Christoph Pohl et al.|New England Journal of Medicine|2007Cited by 258